Cancer focus Myrexis is a biotechnology company focused on discovering, developing, and commercializing novel cancer therapies with potential first-in-class or best-in-class profiles, signaling opportunities for strategic multiple partnering or licensing discussions around innovative oncology programs.

Clinical to preclinical The pipeline spans clinical and preclinical candidates with distinct mechanisms and novel structures, suggesting potential co-development, collaboration, or out-licensing opportunities for programs at various development stages.

Limited scale With 11-50 employees, Myrexis is a lean organization likely seeking strategic alliances to access larger clinical and manufacturing capabilities, commercialization platforms, and capital resources.

Tech foundations Their tech stack includes AWS, Joomla, React, and PHP, indicating a modern but lightweight digital footprint that may benefit from partner-driven digital health, data platforms, or analytics collaborations.

Revenue range Current revenue is in the mid single digits to mid double digits ($25M–$50M), suggesting room for scalable partnerships, licensing deals, or milestone-driven collaborations to accelerate pipeline progression.